SI2981822T1 - Sestavki in postopki za modulacijo rastnega dejavnika - Google Patents
Sestavki in postopki za modulacijo rastnega dejavnikaInfo
- Publication number
- SI2981822T1 SI2981822T1 SI201431717T SI201431717T SI2981822T1 SI 2981822 T1 SI2981822 T1 SI 2981822T1 SI 201431717 T SI201431717 T SI 201431717T SI 201431717 T SI201431717 T SI 201431717T SI 2981822 T1 SI2981822 T1 SI 2981822T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compositions
- methods
- growth factor
- factor modulation
- modulation
- Prior art date
Links
- 239000003102 growth factor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361819840P | 2013-05-06 | 2013-05-06 | |
US201361823552P | 2013-05-15 | 2013-05-15 | |
US201361900438P | 2013-11-06 | 2013-11-06 | |
PCT/US2014/036933 WO2014182676A2 (en) | 2013-05-06 | 2014-05-06 | Compositions and methods for growth factor modulation |
EP14795041.4A EP2981822B1 (en) | 2013-05-06 | 2014-05-06 | Compositions and methods for growth factor modulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2981822T1 true SI2981822T1 (sl) | 2021-08-31 |
Family
ID=51867850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201431717T SI2981822T1 (sl) | 2013-05-06 | 2014-05-06 | Sestavki in postopki za modulacijo rastnega dejavnika |
Country Status (18)
Country | Link |
---|---|
US (12) | US9399676B2 (sl) |
EP (2) | EP2981822B1 (sl) |
JP (5) | JP2016521283A (sl) |
AU (4) | AU2014262843B2 (sl) |
CA (1) | CA2911514A1 (sl) |
CY (1) | CY1123907T1 (sl) |
DK (1) | DK2981822T3 (sl) |
ES (1) | ES2837042T3 (sl) |
HR (1) | HRP20201914T1 (sl) |
HU (1) | HUE052232T2 (sl) |
IL (3) | IL301607A (sl) |
LT (1) | LT2981822T (sl) |
PL (1) | PL2981822T4 (sl) |
PT (1) | PT2981822T (sl) |
RS (1) | RS61778B1 (sl) |
SG (3) | SG10201913751RA (sl) |
SI (1) | SI2981822T1 (sl) |
WO (1) | WO2014182676A2 (sl) |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101282687B (zh) | 2005-10-14 | 2011-11-16 | 应用研究联盟新西兰有限公司 | 监测表面特征的方法和装置 |
WO2007114319A1 (ja) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | 抗体の血中動態を制御する方法 |
JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
PL2708558T3 (pl) | 2008-04-11 | 2018-09-28 | Chugai Seiyaku Kabushiki Kaisha | Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny |
WO2012073992A1 (ja) | 2010-11-30 | 2012-06-07 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
US9179844B2 (en) | 2011-11-28 | 2015-11-10 | Aranz Healthcare Limited | Handheld skin measuring or monitoring device |
US9752113B2 (en) | 2012-03-15 | 2017-09-05 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
US10689609B2 (en) | 2012-03-15 | 2020-06-23 | Flodesign Sonics, Inc. | Acoustic bioreactor processes |
US10322949B2 (en) | 2012-03-15 | 2019-06-18 | Flodesign Sonics, Inc. | Transducer and reflector configurations for an acoustophoretic device |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
US9745548B2 (en) | 2012-03-15 | 2017-08-29 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US10737953B2 (en) | 2012-04-20 | 2020-08-11 | Flodesign Sonics, Inc. | Acoustophoretic method for use in bioreactors |
DK2889377T3 (da) | 2012-08-24 | 2020-03-30 | Chugai Pharmaceutical Co Ltd | Fc?RIIb-Specifik Fc-regionsvariant |
US11236168B2 (en) | 2012-08-24 | 2022-02-01 | Chugai Seiyaku Kabushiki Kaisha | Mouse FcγammaRII-specific Fc antibody |
SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
AU2014262843B2 (en) | 2013-05-06 | 2017-06-22 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
KR102362609B1 (ko) * | 2013-08-01 | 2022-02-11 | 위니베르시트카솔리끄드루뱅 | 항garp 단백질 항체와 그 용도 |
US9745569B2 (en) | 2013-09-13 | 2017-08-29 | Flodesign Sonics, Inc. | System for generating high concentration factors for low cell density suspensions |
WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US10827945B2 (en) * | 2014-03-10 | 2020-11-10 | H. Lee. Moffitt Cancer Center And Research Institute, Inc. | Radiologically identified tumor habitats |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
US9744483B2 (en) | 2014-07-02 | 2017-08-29 | Flodesign Sonics, Inc. | Large scale acoustic separation device |
KR20170066515A (ko) * | 2014-09-30 | 2017-06-14 | 우니베르지타이트 겐트 | 관절 질환의 치료 방법 |
US10603359B2 (en) * | 2014-10-30 | 2020-03-31 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
WO2016073879A2 (en) * | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
PE20221834A1 (es) | 2014-12-19 | 2022-11-29 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina |
SG11201705721WA (en) | 2015-01-14 | 2017-08-30 | Brigham & Womens Hospital Inc | Treatment of cancer with anti-lap monoclonal antibodies |
WO2016125017A1 (en) * | 2015-02-03 | 2016-08-11 | Universite Catholique De Louvain | Anti-garp protein and uses thereof |
CA2974547A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
SG10201910999TA (en) * | 2015-05-15 | 2020-01-30 | Agency Science Tech & Res | Native protein purification technology |
AU2016297248A1 (en) * | 2015-07-22 | 2018-02-15 | Scholar Rock, Inc. | GDF11 binding proteins and uses thereof |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
KR20180043317A (ko) | 2015-08-25 | 2018-04-27 | 히스티드 아게 | 조직 형성 유도용 화합물 및 그것의 용도 |
CA3036652A1 (en) * | 2015-09-15 | 2017-03-23 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
EP3998076A1 (en) * | 2015-09-17 | 2022-05-18 | Histide AG | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
WO2017046226A2 (en) * | 2015-09-17 | 2017-03-23 | Histide Ag | Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof. |
WO2017046229A1 (en) * | 2015-09-17 | 2017-03-23 | Histide Ag | Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
ES2862103T3 (es) * | 2015-09-17 | 2021-10-07 | Histide Ag | Asociaciones farmacéuticas de agonistas de receptores de factor de crecimiento e inhibidores de proteínas de adhesión para la conversión de células neoplásicas en células no neoplásicas y usos de las mismas |
US11230583B2 (en) | 2015-11-26 | 2022-01-25 | Hudson Institute of Medical Research | Inhibin analogs |
BR112018011073A2 (pt) * | 2015-12-18 | 2018-11-21 | Chugai Pharmaceutical Co Ltd | anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização |
WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
KR20180094110A (ko) * | 2016-01-08 | 2018-08-22 | 스칼러 락, 인크. | 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법 |
KR20180122397A (ko) * | 2016-03-11 | 2018-11-12 | 스칼러 락, 인크. | TGFβ1-결합 이뮤노글로불린 및 그의 용도 |
US11046782B2 (en) | 2016-03-30 | 2021-06-29 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination |
US10013527B2 (en) | 2016-05-02 | 2018-07-03 | Aranz Healthcare Limited | Automatically assessing an anatomical surface feature and securely managing information related to the same |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
JP6823167B2 (ja) | 2016-06-13 | 2021-01-27 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | ミオスタチン阻害剤の使用および併用療法 |
EP3484499A4 (en) * | 2016-07-14 | 2020-05-13 | Scholar Rock, Inc. | ANTI-TGFB ANTIBODIES, METHODS AND USES |
MX2019001448A (es) | 2016-08-05 | 2019-09-13 | Chugai Pharmaceutical Co Ltd | Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8). |
AU2017312785A1 (en) | 2016-08-16 | 2019-01-24 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
WO2018057522A1 (en) * | 2016-09-20 | 2018-03-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface |
CA3041517A1 (en) | 2016-10-19 | 2018-04-26 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
JP7102401B2 (ja) | 2016-10-25 | 2022-07-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | クロマトグラフィーデータ解析のための方法およびシステム |
EP3532494A4 (en) * | 2016-10-26 | 2020-06-03 | The Children's Medical Center Corporation | METHOD AND COMPOSITIONS FOR MODULATING TRANSFORMATION GROWTH FACTOR BETA-REGULATED FUNCTIONS |
CA3043180A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
US11116407B2 (en) | 2016-11-17 | 2021-09-14 | Aranz Healthcare Limited | Anatomical surface assessment methods, devices and systems |
WO2018112362A1 (en) * | 2016-12-16 | 2018-06-21 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
DK3366306T3 (en) * | 2016-12-23 | 2022-01-10 | Univ Istanbul Rektoerluegue | Use of some peptides in diagnosis and treatment of diabetes, obesity and metabolic diseases associated thereto |
CN110382530A (zh) * | 2017-01-06 | 2019-10-25 | 供石公司 | 亚型特异性、背景许可性TGFβ1抑制剂及其用途 |
US11155611B2 (en) | 2017-01-06 | 2021-10-26 | Scholar Rock, Inc. | Compositions and methods for making and using anti-myostatin antibodies |
PT3565592T (pt) | 2017-01-06 | 2023-05-31 | Scholar Rock Inc | Tratamento de doenças metabólicas através da inibição da ativação da miostatina |
TWI832600B (zh) | 2017-01-20 | 2024-02-11 | 美商健臻公司 | 骨靶向抗體 |
US10900786B2 (en) | 2017-03-31 | 2021-01-26 | International Business Machines Corporation | Refining an ecological niche model |
EP3606410B1 (en) | 2017-04-04 | 2022-11-02 | Aranz Healthcare Limited | Anatomical surface assessment methods, devices and systems |
DK3621694T3 (da) | 2017-05-09 | 2023-09-11 | Scholar Rock Inc | Lrrc33-inhibitorer og anvendelse heraf |
GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
US20210087240A1 (en) * | 2017-07-19 | 2021-03-25 | Musc Foundation For Research Development | Blocking garp cleavage and methods of use thereof |
US20200206223A1 (en) * | 2017-07-26 | 2020-07-02 | Ftf Pharma Private Limited | Liquid dosage forms of imatinib |
CA3071427A1 (en) * | 2017-07-28 | 2019-01-31 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof |
EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
AU2018364668A1 (en) | 2017-11-09 | 2020-06-11 | Keros Therapeutics, Inc. | Activin receptor type lla variants and methods of use thereof |
JP2021507561A (ja) | 2017-12-14 | 2021-02-22 | フロデザイン ソニックス, インク.Flodesign Sonics, Inc. | 音響トランスデューサドライバ及びコントローラ |
EP3737406A4 (en) | 2018-01-12 | 2021-11-03 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIB VARIANTS AND THEIR METHODS OF USE |
JP2021516966A (ja) * | 2018-03-09 | 2021-07-15 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 組織への生物学的薬物の送達 |
TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
EP3820896A1 (en) | 2018-07-11 | 2021-05-19 | Scholar Rock, Inc. | TGFbeta1 INHIBITORS AND USE THEREOF |
MA52165A (fr) | 2018-07-11 | 2021-06-02 | Scholar Rock Inc | Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée |
TW202005981A (zh) | 2018-07-11 | 2020-02-01 | 美商供石公司 | 高親和性、異構體選擇性之TGFβ1抑制劑及其用途 |
TW202035445A (zh) | 2018-10-10 | 2020-10-01 | 美商帝洛斯療法股份有限公司 | 抗lap抗體變異體及其用途 |
CR20210416A (es) | 2019-01-30 | 2021-09-14 | Scholar Rock Inc | INHIBIDORES ESPECIFICOS DEL COMPLEJO DE LTBP DE TGFß Y USOS DE LOS MISMOS |
GB201908012D0 (en) * | 2019-06-05 | 2019-07-17 | Io Biotech Aps | TGF-Beta vaccine |
JP7350242B2 (ja) * | 2019-07-19 | 2023-09-26 | 国立研究開発法人理化学研究所 | ヒトTGF-βのLAP断片に対する抗体及びその利用 |
EP4021498A4 (en) | 2019-08-28 | 2024-01-03 | Chugai Pharmaceutical Co Ltd | CROSS-SPECIES ANTI-LATENT TGF-BETA-1 ANTIBODIES AND METHOD OF USE |
US20220372136A1 (en) * | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating anemia of chronic disease |
US20220372135A1 (en) * | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
CN111072764A (zh) * | 2019-12-13 | 2020-04-28 | 东莞市东阳光生物药研发有限公司 | 一种重组人Activin A的制备方法 |
CA3166328A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
AU2021205433A1 (en) | 2020-01-11 | 2022-08-18 | Scholar Rock, Inc. | Tgfß inhibitors and use thereof |
WO2021167703A1 (en) | 2020-02-19 | 2021-08-26 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof |
WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
EP4121088A1 (en) * | 2020-03-20 | 2023-01-25 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
AU2022299185A1 (en) | 2021-06-23 | 2024-01-25 | Scholar Rock, Inc. | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
WO2023288277A1 (en) | 2021-07-14 | 2023-01-19 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgfb1 and uses thereof |
GB202203269D0 (en) * | 2022-03-09 | 2022-04-20 | Argenx Iip Bv | TGF-Beta antibodies |
WO2023206188A1 (en) * | 2022-04-28 | 2023-11-02 | Wenzhou Prarucom Bio-Chemical Technology Co. | Method for alleviating pulmonary fibrosis using epidermal growth factor |
Family Cites Families (201)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5262319A (en) | 1985-04-19 | 1993-11-16 | Oncogene Science, Inc. | Method for obtaining bone marrow free of tumor cells using transforming growth factor β3 |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5001225A (en) | 1986-12-08 | 1991-03-19 | Georgetown University | Monoclonal antibodies to a pan-malarial antigen |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5024947A (en) | 1987-07-24 | 1991-06-18 | Cetus Corporation | Serum free media for the growth on insect cells and expression of products thereby |
US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
EP1541682A3 (en) | 1988-09-02 | 2005-07-06 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
JPH03180192A (ja) * | 1989-12-07 | 1991-08-06 | Kirin Brewery Co Ltd | 遺伝子組換えによるヒトプロTGF―β1の製造 |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
AU667460B2 (en) | 1990-10-05 | 1996-03-28 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
DE69128253T2 (de) | 1990-10-29 | 1998-06-18 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
JP3180192B2 (ja) | 1991-01-30 | 2001-06-25 | イハラケミカル工業株式会社 | ジチオカルバミン酸の塩類、その製造方法及び該ジチオカルバミン酸の塩類を使用するイソチオシアネート類の製造方法 |
EP0580737B1 (en) | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
US5573920A (en) | 1991-04-26 | 1996-11-12 | Surface Active Limited | Antibodies, and methods for their use |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
JP3452946B2 (ja) | 1992-02-19 | 2003-10-06 | 協和醗酵工業株式会社 | 抗TGF−βマスキングプロテインモノクローナル抗体 |
ES2193143T3 (es) | 1992-03-05 | 2003-11-01 | Univ Texas | Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
AU5587094A (en) | 1992-10-26 | 1994-05-24 | Kirin Brewery Company, Limited | Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide |
US5951983A (en) | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
DK0690873T3 (da) | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
AU7516694A (en) | 1993-07-30 | 1995-02-28 | Affymax Technologies N.V. | Biotinylation of proteins |
AU696293B2 (en) | 1993-12-08 | 1998-09-03 | Genzyme Corporation | Process for generating specific antibodies |
DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
JP4083794B2 (ja) | 1994-03-29 | 2008-04-30 | レノボ・リミテッド | 創傷の治癒 |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
US5919652A (en) | 1994-11-09 | 1999-07-06 | The Regents Of The University Of California | Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof |
US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5967979A (en) | 1995-11-14 | 1999-10-19 | Verg, Inc. | Method and apparatus for photogrammetric assessment of biological tissue |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
JP2000507939A (ja) | 1996-03-22 | 2000-06-27 | ザ ジェネラル ホスピタル コーポレーション | 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与 |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6348584B1 (en) | 1996-10-17 | 2002-02-19 | John Edward Hodgson | Fibronectin binding protein compounds |
WO1998024893A2 (en) | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM |
JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
AU729035B2 (en) | 1997-06-12 | 2001-01-25 | Novartis Ag | Artificial antibody polypeptides |
WO1999002667A1 (en) | 1997-07-14 | 1999-01-21 | University Of Liege | Mutations in the myostation gene cause double-muscling in mammals |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
JP2001516766A (ja) | 1997-09-19 | 2001-10-02 | デイナ−ファーバー キャンサー インスティチュート,インコーポレイテッド | 免疫反応の細胞内発現抗体仲介制御 |
CA2331410C (en) | 1998-05-06 | 2009-07-14 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
CA2345024C (en) | 1998-10-07 | 2009-05-19 | Stryker Corporation | Modified tgf-.beta. superfamily proteins |
EP1147413B1 (en) | 1999-01-21 | 2006-04-05 | Metamorphix, Inc. | Growth differentiation factor inhibitors and uses therefor |
GB2344886B (en) | 1999-03-10 | 2000-11-01 | Medical Res Council | Selection of intracellular immunoglobulins |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
EP1181041A2 (en) | 1999-04-30 | 2002-02-27 | Curis, Inc. | Morphogen-induced enhancement of fertility |
US6784999B1 (en) | 1999-05-17 | 2004-08-31 | The Florida International University Board Of Trustees | Surface plasmon resonance detection with high angular resolution and fast response time |
TR200200133T2 (tr) | 1999-07-20 | 2002-05-21 | Pharmexa A/S | GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. |
US7358056B1 (en) | 1999-08-30 | 2008-04-15 | Signal Pharmaceuticals | Methods for modulating signal transduction mediated by TGF-β and related proteins |
IT1317922B1 (it) | 2000-10-24 | 2003-07-15 | S I S S A Scuola Internaz Supe | Metodo per identificare in vivo epitopi intracellulari. |
US20030104402A1 (en) | 2001-01-23 | 2003-06-05 | University Of Rochester | Methods of producing or identifying intrabodies in eukaryotic cells |
DE10108240B4 (de) | 2001-02-21 | 2018-06-28 | Leica Microsystems Cms Gmbh | Verfahren zur Abbildung und Vermessung mikroskopischer dreidimensionaler Strukturen |
US20040047891A1 (en) | 2001-02-26 | 2004-03-11 | Sabina Glozman | Systems devices and methods for intrabody targeted delivery and reloading of therapeutic agents |
GB0108165D0 (en) | 2001-03-31 | 2001-05-23 | Univ Manchester | Intracellular analysis |
US20060127893A1 (en) | 2001-07-19 | 2006-06-15 | Stefan Ewert | Modification of human variable domains |
WO2003014960A2 (en) | 2001-08-03 | 2003-02-20 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
GB0201611D0 (en) | 2002-01-24 | 2002-03-13 | Grosveld Frank | Transgenic animal |
WO2003077945A1 (en) | 2002-03-14 | 2003-09-25 | Medical Research Council | Intracellular antibodies |
GB0226723D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Antibodies for in vitro use |
GB0226727D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
US8853362B2 (en) | 2002-05-22 | 2014-10-07 | Esbatech, An Alcon Biomedical Research Unit Llc | Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same |
JP4547561B2 (ja) | 2002-09-16 | 2010-09-22 | ザ ジョンズ ホプキンス ユニバーシティー | メタロプロテアーゼによるミオスタチンの活性化、およびミオスタチン活性の調節法 |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
CA2506128A1 (en) | 2002-11-15 | 2004-06-03 | Medical Research Council | Anti-activated ras antibodies |
GB0226729D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intracellular antibodies |
EP1482309A1 (en) | 2003-05-07 | 2004-12-01 | Institut Curie | Means for detecting protein conformation and applications thereof |
EP1635870A2 (en) | 2003-06-02 | 2006-03-22 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
EP1646655A2 (en) | 2003-07-09 | 2006-04-19 | Eli Lilly And Company | Tgf-beta1 ligands |
US20050164909A1 (en) * | 2003-07-16 | 2005-07-28 | The Ohio State University Research Foundation | Methods and reagents for treating inflammation and fibrosis |
US20080206219A1 (en) | 2003-08-08 | 2008-08-28 | The Regencts Of The University Of California | Novel Indications for Transforming Growth Factor-Beta Regulators |
WO2005023870A1 (ja) * | 2003-09-04 | 2005-03-17 | Riken | TGF-β活性化制御領域の切断面を認識する抗体 |
US7576052B2 (en) | 2003-10-17 | 2009-08-18 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating adipocyte function |
KR100500610B1 (ko) | 2003-10-29 | 2005-07-11 | 한국전기연구원 | 형광 현미경 및 이를 사용한 관측 방법 |
WO2005063817A2 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
SG153874A1 (en) | 2003-12-31 | 2009-07-29 | Schering Plough Ltd | Neutralizing epitope-based growth enhancing vaccine |
US7456149B2 (en) | 2004-03-02 | 2008-11-25 | Acceleron Pharma, Inc. | ALK7 and myostatin inhibitors and uses thereof |
CA2558805C (en) | 2004-03-23 | 2011-09-27 | Eli Lilly And Company | Anti-myostatin antibodies |
AU2005247508A1 (en) | 2004-05-27 | 2005-12-08 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
CA2575563A1 (en) | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
CA2581063C (en) | 2004-09-15 | 2016-03-22 | The Trustees Of The University Of Pennsylvania | Methods for the isolation and expansion of cord blood derived t regulatory cells |
BRPI0516011A (pt) | 2004-09-24 | 2008-08-19 | Amgen Inc | moléculas fc modificadas |
WO2006036074A1 (en) | 2004-09-30 | 2006-04-06 | Orico Limited | Myostatin isoform |
AU2005299355A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Llc | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
AU2005323087A1 (en) | 2004-12-30 | 2006-07-13 | Schering-Plough Pty. Limited | Neutralizing epitope-based growth enhancing vaccine |
NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
PL1850873T3 (pl) | 2005-02-08 | 2019-06-28 | Genzyme Corporation | Przeciwciała przeciwko tgfbeta |
JPWO2006106599A1 (ja) | 2005-03-01 | 2008-09-11 | 国立大学法人京都大学 | 細胞外ドメインシェディングの異常亢進に起因する疾患の予防及び/又は治療のための医薬 |
US8815526B2 (en) | 2005-03-31 | 2014-08-26 | Case Western Reserve University | Methods and reagents for identifying/isolating T regulatory (Treg) cells and for treating individuals |
RS51845B (en) | 2005-04-22 | 2012-02-29 | Eli Lilly And Company | SPECIFIC TGF BETA 1 ANTIBODIES |
PE20061395A1 (es) | 2005-04-25 | 2007-01-15 | Amgen Fremont Inc | Anticuerpos contra miostatina |
AU2006283725B2 (en) | 2005-08-19 | 2012-02-16 | The Trustees Of The University Of Pennsylvania | Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders |
US7635760B2 (en) * | 2005-10-06 | 2009-12-22 | Eli Lilly And Company | Anti-myostatin antibodies |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US8597646B2 (en) | 2005-10-25 | 2013-12-03 | The Johns Hopkins University | Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders |
WO2007109376A2 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Anti-tumor cell antigen antibody therapeutics |
MX2009002470A (es) | 2006-09-05 | 2009-03-20 | Lilly Co Eli | Anticuerpos anti-miostatina. |
JP2008102117A (ja) | 2006-09-21 | 2008-05-01 | Fujifilm Corp | 表面プラズモン増強蛍光センサおよび蛍光検出方法 |
DK2918288T3 (da) | 2006-10-03 | 2017-11-27 | Genzyme Corp | Anvendelse af TGF-beta-antagonister til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi |
WO2009018438A1 (en) | 2007-07-31 | 2009-02-05 | Cornell Research Foundation, Inc. | Protein discovery using intracellular ribosome display |
KR100988471B1 (ko) | 2007-07-06 | 2010-10-18 | 전자부품연구원 | 실시간 세포 분석 장치 및 이를 이용한 세포의 대사 측정방법 |
US20100266577A1 (en) | 2007-07-25 | 2010-10-21 | Felipe Samaniego | Method of Cancer Treatment with Antagonists of FAS Inhibitors |
EP3178496A1 (en) | 2007-08-24 | 2017-06-14 | Keio University | Fstl1 suppressor for use in the treatment of tumours |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
WO2009114702A2 (en) | 2008-03-14 | 2009-09-17 | Humanzyme Limited | Recombinant production of authentic human proteins using human cell expression systems |
GB0809592D0 (en) | 2008-05-27 | 2008-07-02 | Imp Innovations Ltd | Biomaterials |
EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
US20100009424A1 (en) | 2008-07-14 | 2010-01-14 | Natasha Forde | Sonoporation systems and methods |
AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
US8669085B2 (en) | 2009-02-05 | 2014-03-11 | Ut-Battelle, Llc | Transformation of gram positive bacteria by sonoporation |
CN104840944A (zh) | 2009-06-08 | 2015-08-19 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
US8399624B1 (en) | 2009-06-25 | 2013-03-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Acceptor framework for CDR grafting |
US8815779B2 (en) | 2009-09-16 | 2014-08-26 | SwitchGear Genomics, Inc. | Transcription biomarkers of biological responses and methods |
ES2869864T3 (es) | 2009-11-03 | 2021-10-26 | Acceleron Pharma Inc | Procedimientos para el tratamiento de la enfermedad del hígado graso |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
JP6267425B2 (ja) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ, インコーポレイテッド | 筋ジストロフィー治療のためのユートロフィン誘導に関するactriibタンパク質およびその改変体およびその使用 |
US8637637B2 (en) | 2010-01-12 | 2014-01-28 | Bill Nai-Chau Sun | Fc fusion proteins of human growth hormone |
WO2011102483A1 (ja) | 2010-02-19 | 2011-08-25 | 独立行政法人理化学研究所 | ヒトTGF-βのLAPに結合する抗体 |
JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
TW201210612A (en) | 2010-06-03 | 2012-03-16 | Glaxo Group Ltd | Humanised antigen binding proteins |
EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
CN105440134A (zh) | 2010-08-16 | 2016-03-30 | 安姆根公司 | 结合肌肉生长抑制素的抗体、组合物和方法 |
NZ610267A (en) | 2010-10-08 | 2015-05-29 | Hope City | A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use |
EP2703485B1 (en) | 2011-03-30 | 2018-12-26 | National University Corporation University Of Toyama | Method for selecting plasma cells and plasmablasts, and method for producing target antigen-specific antibody |
KR102577578B1 (ko) * | 2011-06-03 | 2023-09-11 | 조마 테크놀로지 리미티드 | Tgf-베타에 특이적인 항체 |
WO2013016452A2 (en) | 2011-07-25 | 2013-01-31 | Vanderbilt University | Cancer treatment using bmp inhibitor |
ES2682254T3 (es) | 2011-08-18 | 2018-09-19 | Affinity Biosciences Pty Ltd | Polipéptidos solubles |
US10071129B2 (en) | 2011-08-30 | 2018-09-11 | Whitehead Institute For Biomedical Research Dana-Farber Cancer Institute, Inc. | Method for identifying bromodomain inhibitors |
EP2766382B1 (en) | 2011-10-10 | 2020-05-06 | City of Hope | Meditopes and meditope-binding antibodies and uses thereof |
PT2780368T (pt) | 2011-11-14 | 2018-03-22 | Regeneron Pharma | Composições e métodos para aumentar a massa muscular e a força muscular antagonizando especificamente gdf8 e/ou activina a |
ES2628075T3 (es) | 2011-12-19 | 2017-08-01 | Synimmune Gmbh | Molécula de anticuerpo biespecífica |
EP2861617A1 (en) | 2012-06-15 | 2015-04-22 | Pfizer Inc. | Improved antagonist antibodies against gdf-8 and uses therefor |
JP6073038B2 (ja) | 2012-08-22 | 2017-02-01 | モガム バイオテクノロジー リサーチ インスティチュート | 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用 |
EA033536B1 (ru) | 2012-09-13 | 2019-10-31 | Bristol Myers Squibb Co | Основанные на фибронектине каркасные доменные белки, которые связываются с миостатином |
AU2013341353B2 (en) | 2012-11-06 | 2017-03-16 | Children's Medical Center Corporation | Compositions and methods for modulating cell signaling |
WO2014093531A1 (en) | 2012-12-11 | 2014-06-19 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Modulation of myofiber repair by anti-myostatin in strategies with stem cells |
WO2014144573A2 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Multimerization technologies |
AU2014262843B2 (en) | 2013-05-06 | 2017-06-22 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
EP2832747A1 (en) | 2013-08-01 | 2015-02-04 | Université Catholique de Louvain | Anti-GARP protein and uses thereof |
KR102362609B1 (ko) | 2013-08-01 | 2022-02-11 | 위니베르시트카솔리끄드루뱅 | 항garp 단백질 항체와 그 용도 |
CA2947967A1 (en) | 2014-05-06 | 2015-11-12 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
EP3215175A4 (en) * | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
-
2014
- 2014-05-06 AU AU2014262843A patent/AU2014262843B2/en active Active
- 2014-05-06 LT LTEP14795041.4T patent/LT2981822T/lt unknown
- 2014-05-06 ES ES14795041T patent/ES2837042T3/es active Active
- 2014-05-06 EP EP14795041.4A patent/EP2981822B1/en active Active
- 2014-05-06 EP EP20193425.4A patent/EP3816625A1/en active Pending
- 2014-05-06 SI SI201431717T patent/SI2981822T1/sl unknown
- 2014-05-06 SG SG10201913751RA patent/SG10201913751RA/en unknown
- 2014-05-06 WO PCT/US2014/036933 patent/WO2014182676A2/en active Application Filing
- 2014-05-06 PT PT147950414T patent/PT2981822T/pt unknown
- 2014-05-06 CA CA2911514A patent/CA2911514A1/en active Pending
- 2014-05-06 HU HUE14795041A patent/HUE052232T2/hu unknown
- 2014-05-06 PL PL14795041T patent/PL2981822T4/pl unknown
- 2014-05-06 SG SG10201800800YA patent/SG10201800800YA/en unknown
- 2014-05-06 JP JP2016513010A patent/JP2016521283A/ja active Pending
- 2014-05-06 RS RS20201467A patent/RS61778B1/sr unknown
- 2014-05-06 DK DK14795041.4T patent/DK2981822T3/da active
- 2014-05-06 IL IL301607A patent/IL301607A/en unknown
- 2014-05-06 SG SG11201508681QA patent/SG11201508681QA/en unknown
-
2015
- 2015-07-09 US US14/795,033 patent/US9399676B2/en active Active
- 2015-07-09 US US14/795,007 patent/US9573995B2/en active Active
- 2015-07-09 US US14/795,022 patent/US9580500B2/en active Active
- 2015-07-09 US US14/795,012 patent/US9758576B2/en active Active
- 2015-10-21 IL IL242193A patent/IL242193B/en active IP Right Grant
-
2016
- 2016-06-20 US US15/187,278 patent/US9758577B2/en active Active
-
2017
- 2017-01-09 US US15/401,386 patent/US20170210798A1/en not_active Abandoned
- 2017-01-12 US US15/404,663 patent/US10597443B2/en active Active
- 2017-05-15 JP JP2017096629A patent/JP2017200915A/ja not_active Withdrawn
- 2017-05-30 AU AU2017203611A patent/AU2017203611C1/en active Active
- 2017-07-26 US US15/659,974 patent/US20180016332A1/en not_active Abandoned
- 2017-08-08 US US15/671,217 patent/US20180022798A1/en not_active Abandoned
-
2018
- 2018-12-04 US US16/209,078 patent/US10981981B2/en active Active
-
2019
- 2019-05-31 AU AU2019203834A patent/AU2019203834A1/en not_active Abandoned
- 2019-09-04 JP JP2019161176A patent/JP6796695B2/ja active Active
-
2020
- 2020-01-07 US US16/736,207 patent/US20200131259A1/en active Pending
- 2020-11-16 JP JP2020189967A patent/JP2021050201A/ja active Pending
- 2020-12-01 HR HRP20201914TT patent/HRP20201914T1/hr unknown
- 2020-12-02 CY CY20201101140T patent/CY1123907T1/el unknown
-
2021
- 2021-03-09 US US17/196,256 patent/US11827698B2/en active Active
- 2021-03-16 IL IL281549A patent/IL281549B2/en unknown
- 2021-06-28 AU AU2021204415A patent/AU2021204415A1/en active Pending
-
2023
- 2023-07-20 JP JP2023118376A patent/JP2023156328A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281549A (en) | Preparations and methods for growth factor modulation | |
IL289821A (en) | Preparations and methods for immunotherapy | |
HK1220387A1 (zh) | 用於免疫療法的組合物和方法 | |
IL244081A0 (en) | Preparations and methods for modulating RNA | |
ZA201506710B (en) | Compositions and methods for enhancing plant growth | |
PT3524680T (pt) | Composições e métodos para modular a expressão de ttr | |
EP2978300A4 (en) | COMPOSITIONS AND METHODS FOR INCREASING MICROBIAL STABILITY | |
HK1218659A1 (zh) | 用於調節 表達的組合物和方法 | |
IL285527A (en) | Preparations and methods for immunotherapy | |
ZA201602073B (en) | Compositions and methods for improving plant growth | |
EP2744490A4 (en) | METHOD AND COMPOSITIONS FOR IMPROVING GROWTH HORMONES |